Moderna (MRNA) Stock Forecast: What Could Drive It in 2026
Short answer
What is actually driving Moderna (MRNA) right now is Respiratory franchise beyond COVID: Moderna is trying to convert a single-product COVID business into a broader respiratory portfolio. Q1 2026 revenue is ~$400 million. If that keeps playing out, the setup is favourable; the risk to it is revenue has fallen dramatically from pandemic highs and COVID demand remains uncertain, so the current business does not cover operating costs. No one can predict where MRNA trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Moderna (MRNA) higher?
1. Respiratory franchise beyond COVID
Moderna is trying to convert a single-product COVID business into a broader respiratory portfolio. mRESVIA (RSV) is already approved for older adults, and Europe cleared mNEXSPIKE plus the mCOMBRIAX combination shot. A U.S. flu decision (mRNA-1010) with a PDUFA date around August 2026 is the next major catalyst, though the program has already had a regulatory setback.
2. Oncology optionality via Merck partnership
Intismeran autogene (mRNA-4157), the personalized cancer vaccine developed with Merck, is the highest-upside pipeline bet. Five-year Phase 2b adjuvant melanoma data showed a roughly 49% reduction in recurrence or death when combined with Keytruda versus Keytruda alone, and Phase 3 trials are expanding across melanoma, lung, bladder, and kidney cancers.
3. Cost discipline and a path to break-even
Management has framed 2026 around disciplined spending, targeting cash flow break-even by 2028 while preserving a large cash and investments balance (several billion dollars). International sales, including a U.K. government partnership, made up the bulk of recent revenue, which management points to as evidence of a more diversified base.
4. Platform leverage across many programs
Moderna carries one of the largest clinical-stage mRNA pipelines (dozens of candidates), spanning respiratory, latent viruses, rare diseases, and oncology. The thesis is that a single validated platform can produce multiple shots on goal, so a few approvals could re-rate the business even if individual programs fail.
What could weigh on MRNA?
Revenue has fallen dramatically from pandemic highs and COVID demand remains uncertain, so the current business does not cover operating costs. The company is loss-making and burning cash, making it dependent on pipeline approvals landing on schedule. Regulatory risk is concrete: the FDA issued a Refusal-to-File letter for the flu vaccine earlier in 2026, and shifting U.S. vaccine policy adds uncertainty. Large legal settlements (such as the Arbutus and Genevant charge) can swing reported results, and much of the long-term value depends on the Merck-partnered cancer vaccine succeeding in Phase 3, which is far from guaranteed.
Where MRNA trades today
A forecast starts from where the stock actually is. These are MRNA's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for MRNA as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a MRNA forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the MRNA guide and whether MRNA is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the MRNA outlook
The bottom line: what is driving Moderna (MRNA) is Respiratory franchise beyond COVID, with q1 2026 revenue at ~$400 million. If that keeps playing out the setup is favourable; the risk is revenue has fallen dramatically from pandemic highs and COVID demand remains uncertain, so the current business does not cover operating costs. No one can predict the price, so treat any MRNA forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around MRNA with Walnut
Use Moderna as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Moderna (MRNA)?
+
No one can reliably predict where MRNA will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Moderna higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive MRNA higher?
+
The main growth drivers are Respiratory franchise beyond COVID; Oncology optionality via Merck partnership; Cost discipline and a path to break-even. Whether they play out is the real question, not a guaranteed path.
What are the risks to MRNA?
+
Revenue has fallen dramatically from pandemic highs and COVID demand remains uncertain, so the current business does not cover operating costs. The company is loss-making and burning cash, making it dependent on pipeline approvals landing on schedule. Regulatory risk is concrete: the FDA issued a Refusal-to-File letter for the flu vaccine earlier in 2026, and shifting U.S. vaccine policy adds uncertainty. Large legal settlements (such as the Arbutus and Genevant charge) can swing reported results, and much of the long-term value depends on the Merck-partnered cancer vaccine succeeding in Phase 3, which is far from guaranteed.
Will MRNA stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Moderna's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is MRNA a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the MRNA "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.